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Background: Anti-malarial drug resistance continues to be a leading threat to ongoing malaria control efforts and
calls for continued monitoring of the efficacy of these drugs in order to inform national anti-malarial drug policy
decision-making. This study assessed the therapeutic efficacy and safety of artemether-lumefantrine (AL)(Coartem®)
for the treatment of uncomplicated Plasmodium falciparum malaria in two sentinel high malaria transmission districts in
the Eastern Province of Zambia in persons aged six months and above, excluding women aged 12 to 18 years.
Methods: This was an observational cohort of 176 symptomatic patients diagnosed with uncomplicated Plasmodium
falciparum mono-infection. A World Health Organization (WHO)-standardized 28-day assessment protocol was used to
assess clinical and parasitological responses to directly observed AL treatment of uncomplicated malaria. DNA
polymerase chain reaction (PCR) analysis for molecular markers of AL resistance was conducted on positive blood
samples and differentiated recrudescence from re-infections of the malaria parasites.
Results: All patients (CI 97.6-100) had adequate clinical and parasitological responses to treatment with AL. At the time
of enrolment, mean slide positivity among study participants was 71.8% and 55.2% in Katete and Chipata, respectively.
From a mean parasite density of 55,087, 98% of the study participants presented with zero parasitaemia by day 3 of the
study. Fever clearance occurred within 24 hours of treatment with AL. However mean parasite density declines were
most dramatic in participants in the older age. No adverse reactions to AL treatment were observed during the study.
Conclusion: AL remains a safe and efficacious drug for the treatment of uncomplicated Plasmodium falciparum malaria
in Zambia, endemic for malaria, with some provinces experiencing high transmission intensity. However, the delayed
parasite clearance in younger patients calls for further sentinel and periodical monitoring of AL efficacy in different
areas of the country.
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Malaria is a parasitic infection endemic in Zambia. It is re-
ported to be among the 10 top causes of morbidity and
mortality in health facilities in the country [1]. A 50%
decline in malaria cases and deaths was observed between
the years 2000 to 2010 [2] and this was attributed to
improved funding, technical assistance and scale up of
cost-effective preventive and curative interventions [3].
However, continued success in controlling malaria con-
tinues to be threatened by the development of resistance
to anti-malarial medicines, as evidenced in Zambia with
resistance development to chloroquine and sulphadoxine-
pyrimethamine [4,5]. In this regard, following recommen-
dations by the World Health Organization (WHO) [6,7],
Zambia reviewed its malaria treatment policy in 2003 re-
moving Chloroquine (CQ) as the first-line treatment for
uncomplicated malaria and replaced it with artemisinin
combination therapy (ACT), with the drug of choice being
the co-formulated artemether-lumefantrine (AL) (20 mg
artemether and 120 mg lumefantrine) [5]. AL is recom-
mended for the treatment of uncomplicated malaria be-
cause of its rapid reduction of parasite load as a result of
the action of the artemisinin component and continued
elimination of residual parasites by lumefantrine which re-
sults in a rapid clinical response [6,7]. ACT may reduce
the development of parasite resistance subsequently by
contributing to the reduction of malaria transmission [8].
The policy change from CQ to AL in 2003 was well ac-
cepted by users on account of its proven therapeutic effi-
cacy even against multi-drug resistant parasites, optimal
tolerability and safety profile. However, continued use of
these anti-malarial medicines including, AL is threatened
by the development of parasite resistance. However,
currently, there are no alternative anti-malarial drugs
available with proven therapeutic efficacy even against
multi-drug resistant parasites, optimal tolerability and
safety profile as artemisinin-based combinations [9]. In
order to ensure effective malaria case management, it may
be imperative to preserve the user-life of ACT. For this
reason, National Malaria Control Programmes should
conduct regular therapeutic efficacy testing of anti-
malarial drugs to provide timely, relevant and reliable in-
formation to guide malaria treatment policy development.
This study was conducted to provide efficacy and
safety data on artemether-lumefantrine following a
standard WHO 28-day follow-up therapeutic efficacy




This was a one-arm prospective study conducted in May
2012. The study assessed clinical and parasitological re-
sponses after administration of anti-malarial treatmentwith AL to eligible patients aged six months (>5kgs
weight) and above, excluding women of the age group
(12 to 18 years) suffering from uncomplicated falcip-
arum malaria.Study site
The study was conducted in two primary health facilities
located in Chipata and Katete districts of Eastern Province
in Zambia (Figure 1). These sites were selected based on
their malaria epidemiological and geographic profile. The
selected study sites had functional laboratories equipped
with optimal microscopy services for malaria diagnosis
and were situated near a second level district hospital for
referrals of severe malaria case management if required.Study population
The population consisted of consenting patients with
uncomplicated Plasmodium falciparum malaria infection
seeking care at the selected study primary health care
facilities who were aged six months (>5kgs weight) and
above, excluding women of the age group 12 to 18 years
as requesting this age group to take a pregnancy test and
initiate contraception is not acceptable in the local
context. All enrolled patients were treated with AL on
site as directly observed treatment and monitored for
28 days, as per recommendation for evaluating clinical
and parasitological response for drugs such as AL that
have a half-life of less than seven days [10]. Health care
services including follow-up for any illness related to
malaria were provided free of charge to the study
patients regardless of treatment outcome.Sample size
Assuming a 5% treatment failure rate to AL, a 95%
confidence level and a precision around the estimate of
5%, 73 patients were targeted as a minimum for inclu-
sion into the study. With a 20% increase to allow loss to
follow-up and withdrawals during the 28-day follow-up
period, 87 patients were planned to be included into the
study. The study recruited a total of 177 patients overall.Inclusion criteria
Symptomatic patients aged six months (>5kgs weight)
and above, excluding women of the age group 12 to
18 years, self-presenting to health facilities with uncom-
plicated malaria due to mono-infection of P. falciparum
detected by microscopy at parasitaemia of 1,000 to
200,000/μl asexual forms, axilliary temperature ≥37.5°C,
willing to comply with the study protocol for the duration
of the study were included. A detailed inclusion criteria is
provided elsewhere [10].
Figure 1 Location of districts and study sites where the study was conducted.
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Patients with general danger signs or signs of severe
falciparum malaria; unable to drink, or breast feed (in
case of children), severe vomiting; reported history of
convulsion seven days prior to patient contact; presence
of lethargy or decreased consciousness; inability to sit or
stand, were all excluded. Patients who failed to complete
treatment due to persistent vomiting of the treatment or
failed to attend scheduled visits during the first three days
or withdrew their consent were also excluded. A detailed
list of exclusion criteria is provided elsewhere [10].Follow-up and loss to follow up
Parents or guardians of children were instructed to
return to the health centre at any time if they had any
general danger signs as described under exclusion cri-
teria above. The study team made home visits as follow
ups for study participants that were late for their sched-
uled visits. Patients who failed to return on days 1 and
2 and missed one dose of the treatment or enrolled
patients who could not attend scheduled visits were
considered lost to follow up (LFU) and excluded from
the final analysis.Anti-malarial treatment
AL was obtained from WHO and administered by a
qualified Medical Officer following a treatment regime
of two daily doses for three days based on the patient’s
weight [7]. The day a patient was enrolled and received
the first dose of AL was designated ‘Day 0 or D0’.
Enrolled patients were observed for a minimum of
30 minutes after treatment to ensure that they did not
vomit the drugs. Patients with persistent vomiting were
excluded from the study and immediately referred to
the district hospital for appropriate management. A case
report form was kept for recording adverse events.
Patients with fever over 38°C were treated with para-
cetamol or any available antipyretic. Parents or guard-
ians were instructed in the use of tepid sponging for
children under five years of age. Patients were advised
not to take herbal remedies during the study to avoid
effects that would confound interpretation for findings.Classification of responses to treatment
On the basis of parasitological and clinical outcome of
treatment with AL, patients were classified according to
the WHO definition of therapeutic responses [10].
Table 1 Number of patients assessed and loss for follow
up at each scheduled visit
Day of follow up 0 1 2 3 7 14 21 28
Patients assessed at visit 176 173 172 172 172 171 171 171
Loss to follow up 0 3 1 0 0 1 0 0
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The development of danger signs for severe malaria on
days 1, 2, or 3 in the presence of parasitaemia; parasit-
aemia on day 2 higher than the day 0 count irrespective of
axilliary temperature; parasitaemia on day 3 with axilliary
temperature ≥37.5°C; parasitaemia on day 3 ≥ 25% of
count on day 0.
Late clinical failure (LCF)
The development of danger signs for severe malaria after
day 3 in the presence of parasitaemia, without previously
meeting any of the criteria of ETF; presence of parasit-
aemia and axilliary temperature ≥37.5°C or history of
fever on any day from day 4 to day 28, without previ-
ously meeting any of the criteria of ETF.
Late parasitological failure (LPF)
The presence of parasitaemia on any day from day 7 to day
28 and axilliary temperature <37.5°C, without previously
meeting any of the criteria for ETF or LCF.
Adequate Clinical and Parasitological Response (ACPR)
It is the absence of parasitaemia on day 28 irrespective of
axilliary temperature without previously meeting any of
the criteria for ETF, LTF, or LPF. The secondary outcomes
were fever clearance rate; proportion of patients who had
fever cleared on days 1, 2, and 3. Parasite clearance rate:
proportion of patients with negative thick blood film
smears on days 1, 2, and 3; Gametocyte carriage: propor-
tion of patients with gametocytes during the course of the
study.
Genotyping of malaria parasites
Genotype analysis (nested PCR amplification) was con-
ducted at the National Malaria Control Centre molecular
laboratory based on genetic diversity among the malaria
parasite genes msp1, msp2 and glurp. The technique differ-
entiated “recrudescence” from a newly acquired infection
through a comparison of pre- and post-parasite strain
genotype profiles. Details of the protocol used in this ana-
lysis are described in detail elsewhere [11].
Data analysis
Data from both clinical and parasitological assessments
from the case report for each study participant were
entered into the WHO standardized Microsoft excel
data collection form [10]. This form was used both for
data management and analysis. Additional analysis was
conducted with Microsoft excel. All data was independ-
ently double blind entered.
Ethical considerations
Approval to conduct the study was obtained from the
Tropical Diseases Research Centre ethics committeebased in Ndola, Zambia. Permission to conduct the study
was obtained from the Ministry Of Health. Informed con-
sent was sought from all study participants. Guardians
provided assent for the participation of the persons under
the consenting age. They were asked to read or have read
to them, understand and sign/thumbprint an informed
consent form. The consent was available in English and
explained in vernacular to the patient, parent or guardian.
The benefits and potential risks were explained and a sig-
nature requested on the consent form. Confidentiality was
maintained through ensuring all patients’ information
used unique identifiers. All data collection forms were
stored in locked files.
Results
Patient characteristics
A total of 142 and 230 eligible patients from Katete and
Chipata, respectively, were screened during the study.
The slide positivity rate was 71.8% (102/142) and 55.2%
(127/230) respectively for Katete and Chipata, which
translated into an overall slide positivity of 61.6% (229/372)
for both study sites. Following the eligibility requirements,
a total of 177 (88 Katete and 89 Chipata) were enrolled into
the study (Table 1). Due to one loss to follow-up, the total
analysable population was 176 (Table 1), which consisted of
49.7% female participants. In the study there were 51%
(91/176) under-five participants, while 36% (63/176)
comprised of patients between the age of 5 and 15. The
remaining study participants were above the age of 15
(13%( 23/176)). The under-fives enrolled population
had the highest mean axilliary temperature as well as
parasite densities when compared to the higher age
groups (Table 2).
Primary study outcomes
A total of 171 evaluable patients were assessed up to day
28. Five patients were lost to follow up during the study
period. Analysis of PCR uncorrected data estimated
adequate clinical and parasitological response (ACPR) as
89.5% (CI 83.9 - 93.6) in patients treated with AL. No
patients showed early treatment failures (ETF), while late
clinical failure (LCF) was reported in 6 study partici-
pants (3.5% (CI 1.3, 7.5)). Late parasitological failure
(LPF) was observed in 12 (7.0% (CI 3.7, 11.9)) of the
evaluated study population (Table 3). All reported treat-
ment failures were observed in the age groups under the
age of 15. The Katete site with 9 (i.e., seven below five
Table 2 Summary of patient characteristics




Under 5 yrs 91 (51%) 11.9 89 (97.8%) 2 (0%) 38.3 67091.6 0 (0%)
5-15 yrs 63 (36%) 22.2 63 (100%) 0 (0%) 38.2 43987.4 0 (0%)
Over 15 yrs 23 (13%) 52.2 22 (95.7%) 1 (0%) 37.5 39607.6 1 (0%)
ALL ages 177 (100%) 20.8 174 (98.3%) 3 (1.7%) 38.1 55087.3 1 (0.5%)
*Mean estimates from Day 0 of the study.
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more LPF than Chipata with three all aged between five
and fifteen). Three LCF were reported in each of the two
sites. In Katete all the participants were aged below five,
whereas in Chipata two were under the age of five and
one participant was over five, but below 15 years. The
Kaplan Meier survival analysis of the PCR uncorrected
data showed estimates of success of 1.00 between Day 0
to 6; 0.98 from day 7 to 20; 0.94 from day 21 to 27 and 0.9
on Day 28. The estimate of failure cumulative incidence
was 0.00 from Day 0 to 6; 0.02 from Day 7 to 20; 0.06
from Day 21 to 27 and 0.1 on Day 28. The proportion of
success and failure of the study participants at each point
in time was not significant at the 95% (CI, 0.884, 1.026)
and (−0.026, 0.116), respectively (Figure 2A).
PCR genotyped cure rate showed that 100% (CI 97.6 –
100, n = 153)) of the patients had ACPR to the AL treat-
ment (Table 4). The Kaplan Meier survival analysis of
the PCR corrected data showed estimates of success of
1.00 from day 0 to 28, translating into an estimate of
failure cumulative incidence of 0.00 from day 0 to 28
(Figure 2B). The proportion of study participants with
gametocytes on Day 0 was 0.5% (1/176) and by Day 7
was 1.1% (2/176). There were no gametocytes observed
on Days 14 and 21. However on Day 28, 2 (1.1%) study
participants had gametocytes. During the 28-day follow
up no adverse events were observed.Table 3 Summary of classification of treatment outcomes
(PCR uncorrected)
Classification Number Proportion Lower 95% CI Upper 95% CI
ETF 0 0.000 0.000 0.021
LCF 6 0.035 0.013 0.075
LPF 12 0.070 0.037 0.119





Abbreviations: ACPR Adequate Clinical and Parasitological Response, ETF Early
Treatment Failure, LCF Late Clinical Failure, LPF Late Parasitological Failure,
LFU Loss to Follow Up, WTH Withdrawn.Secondary study outcomes
A hundred percent (100%) reduction of mean parasit-
aemia was observed in all age groups on Day 1. However,
on Day 2 under five children showed 99.7% and the 5 to
15 age groups showed 98% decline. Plasmodium falcip-
arum parasitaemia were recorded in the under-five age
group on days 3 to day 28 as follows: Day3: 2.2% (2/90),
Day 7: 3.3% (3/90), Day 14: 1.1% (1/90) , Day 21: 6.7%
(6/90) and Day 28: 4.4% (4/90). Likewise, parasitaemia was
reported in the age group 5 to 15 on Day 3: 6.4% (4/63)
and Day 28: 9.5% (6/63) (Figure 3). The two study partici-
pants who had parasitaemia on day 3 did not meet all the
criteria required to be withdrawn from the study based on
an ETF classification as the parasitaemia observed was less
than that of day 0 and they were both afebrile. There was
a general reduction in mean fever within 24 hours ofFigure 2 Kaplan Meier curves showing treatment success
cumulative proportion for the population under study for
artemether lumefantrine up to day 28 of follow-up ((A)
PCR-uncorrected and (B) PCR-corrected)).
Table 4 Summary of Classification of treatment outcomes
(PCR - corrected)
Classification Number Proportion Lower 95% CI Upper 95% CI
ETF 0 0.000 0.000 0.024
LCF 0 0.000 0.000 0.024
LPF 0 0.000 0.000 0.024





Abbreviations: ACPR Adequate Clinical and Parasitological Response, ETF Early
Treatment Failure, LCF Late Clinical Failure, LPF Late Parasitological Failure,
LFU Loss to Follow Up, WTH Withdrawn.
Figure 4 Parasitaemia clearance according to day and age of
study participant.
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of the 28-day follow up (Figure 4).Discussion
This study has demonstrated that fixed dose artemether-
lumefantrine is effective for the treatment of uncompli-
cated P. falciparum malaria in all ages in areas with high
malaria transmission intensity. The study comes nine
years after its adoption as first-line anti-malarial in
Zambia [5]. The high cure rates and tolerability of AL
obtained in this study were consistent with those re-
ported previously [12-14].
WHO recommends a review of treatment policy for un-
complicated malaria at 10% treatment failure [10]. This
cut-off point was not reached in this study. Treatment fail-
ures have been associated primarily with either suboptimal
plasma drug levels of the anti-malarial, re-infections or
gene mutations resulting in parasite resistance [15,16].
This study did not record any early treatment failure, sug-
gesting that there may not be any need to include analysis
of drug plasma levels in similar future studies [17].Figure 3 Fever (axilliary temperature ≥37.5°C) clearance
according to day of visit and age of study participant.However, the observation of asexual parasitaemia on days
3 and 7, in the predominately non-immune under-five age
group raises concerns even though these infections were
determined to be new infections. This finding requires
further study to better understand transmission dynamics
effects on parasitaemia persistence in a population post
treatment. Slower parasite clearance in vivo to artemisi-
nins has been reported elsewhere, particularly on the
Thai-Cambodian border [18,19].
Pre-treatment gametocytaemia was cleared by day 7, in-
dicating that AL is still effective with regard to gametocyte
clearance, and, suggesting a potential role in transmission
reduction. Thus further suggesting a continued role in
malaria control for therapeutic interventions, particularly
with current calls for malaria elimination in most endemic
countries [20,21].
Zambia is among a few countries in the sub-region
which has conducted or maintained regular studies in its
sentinel sites in different areas across the country repre-
senting the different geographical and epidemiological
profiles to monitor therapeutic efficacy of anti-malarial
medicines. In the past three to four years efficacy studies
faced a challenge on account of reduced malaria cases,
which made it difficult and expensive to attain the
required sample size. Therefore, to achieve the required
sample size in this study, for the first time in Zambia,
persons of all ages were enrolled rather than restricting
the study to children under the age of five years as was
the case previously [10]. Thus in part, the findings of
this study reflect a detected efficacy influenced by previ-
ous exposure to malaria infection.
A key limitation of the study was the lack of a corre-
sponding assessment in anaemia in the study participants,
which would have provided data on longitudinal effects of
malaria parasite infection in the study areas. An important
strength of the study is that the study provides vital data
collected in a high P. falciparum transmission (>15%
parasitaemia) area in Zambia.
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Artemether-lumefantrine remains a safe and effective
drug for the treatment of uncomplicated falciparum
malaria in Zambia. AL is well tolerated in all ages when
administered. The efficacy of this ACT needs to be care-
fully monitored periodically since treatment failures can
occur due to resistance as well as sub- therapeutic levels
due to non-compliance of therapeutic dosage. It is also
important to strengthen routine monitoring of anti-
malarial efficacy particularly in light of planned elimin-
ation efforts which will in part depend on therapeutic
interventions.
Abbreviations
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